The Role of Health Systems Factors in Facilitating Access to Psychotropic Medicines: A Cross-Sectional Analysis of the WHO-AIMS in 63 Low- and Middle-Income Countries
Background:
Neuropsychiatric conditions comprise 14% of the global burden of disease and 30% of all noncommunicable disease. Despite the existence of cost-effective interventions, including administration of psychotropic medicines, the number of persons who remain untreated is as high as 85% in low- and middle-income countries (LAMICs). While access to psychotropic medicines varies substantially across countries, no studies to date have empirically investigated potential health systems factors underlying this issue.
Methods and Findings:
This study uses a cross-sectional sample of 63 LAMICs and country regions to identify key health systems components associated with access to psychotropic medicines. Data from countries that completed the World Health Organization Assessment Instrument for Mental Health Systems (WHO-AIMS) were included in multiple regression analyses to investigate the role of five major mental health systems domains in shaping medicine availability and affordability. These domains are: mental health legislation, human rights implementations, mental health care financing, human resources, and the role of advocacy groups. Availability of psychotropic medicines was associated with features of all five mental health systems domains. Most notably, within the domain of mental health legislation, a comprehensive national mental health plan was associated with 15% greater availability; and in terms of advocacy groups, the participation of family-based organizations in the development of mental health legislation was associated with 17% greater availability. Only three measures were related with affordability of medicines to consumers: level of human resources, percentage of countries' health budget dedicated to mental health, and availability of mental health care in prisons. Controlling for country development, as measured by the Human Development Index, health systems features were associated with medicine availability but not affordability.
Conclusions:
Results suggest that strengthening particular facets of mental health systems might improve availability of psychotropic medicines and that overall country development is associated with affordability.
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
The Role of Health Systems Factors in Facilitating Access to Psychotropic Medicines: A Cross-Sectional Analysis of the WHO-AIMS in 63 Low- and Middle-Income Countries. PLoS Med 9(1): e32767. doi:10.1371/journal.pmed.1001166
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001166
Souhrn
Background:
Neuropsychiatric conditions comprise 14% of the global burden of disease and 30% of all noncommunicable disease. Despite the existence of cost-effective interventions, including administration of psychotropic medicines, the number of persons who remain untreated is as high as 85% in low- and middle-income countries (LAMICs). While access to psychotropic medicines varies substantially across countries, no studies to date have empirically investigated potential health systems factors underlying this issue.
Methods and Findings:
This study uses a cross-sectional sample of 63 LAMICs and country regions to identify key health systems components associated with access to psychotropic medicines. Data from countries that completed the World Health Organization Assessment Instrument for Mental Health Systems (WHO-AIMS) were included in multiple regression analyses to investigate the role of five major mental health systems domains in shaping medicine availability and affordability. These domains are: mental health legislation, human rights implementations, mental health care financing, human resources, and the role of advocacy groups. Availability of psychotropic medicines was associated with features of all five mental health systems domains. Most notably, within the domain of mental health legislation, a comprehensive national mental health plan was associated with 15% greater availability; and in terms of advocacy groups, the participation of family-based organizations in the development of mental health legislation was associated with 17% greater availability. Only three measures were related with affordability of medicines to consumers: level of human resources, percentage of countries' health budget dedicated to mental health, and availability of mental health care in prisons. Controlling for country development, as measured by the Human Development Index, health systems features were associated with medicine availability but not affordability.
Conclusions:
Results suggest that strengthening particular facets of mental health systems might improve availability of psychotropic medicines and that overall country development is associated with affordability.
: Please see later in the article for the Editors' Summary
Zdroje
1. DemyttenaereKBruffaertsRPosada-VillaJGasquetIKovessV 2004 Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 291 2581 2590
2. WHO 2001 The world health report 2001 - mental health: new understanding, New Hope Geneva World Health Organization
3. MathersCDLoncarD 2006 Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3 e442
4. PrinceMPatelVSaxenaSMajMMaselkoJ 2007 No health without mental health. Lancet 370 859 877
5. WHO 2008 mhGAP Mental Health Action Programme: scaling up care for mental, neurological and substance abuse disorders Geneva World Health Organization
6. SaxenaSSharanPGarridoMSaracenoB 2006 World Health Organization's Mental Health Atlas 2005: implications for policy development. World Psychiatry 5 179 184
7. WHO 2005 Mental health atlas 2005 Geneva WHO
8. SaxenaSThornicroftGKnappMWhitefordH 2007 Resources for mental health: scarcity, inequity, and inefficiency. Lancet 370 878 889
9. PatelV 2009 The future of psychiatry in low- and middle-income countries. Psychol Med 39 1759 1762
10. PatelVMajMFlisherAJMJDESKoschorkeM 2010 Reducing the treatment gap for mental disorders: a WPA survey. World Psychiatry 9 169 176
11. BhanaAPetersenIBaillieKLFlisherAJ The Mhapp Research Programme C 2010 Implementing the World Health Report 2001 recommendations for integrating mental health into primary health care: a situation analysis of three African countries: Ghana, South Africa and Uganda. Int Rev Psychiatry 22 599 610
12. WHO 2008 mhGAP: Mental health gap action programme Geneva World Health Organization
13. PatelVThornicroftG 2009 Packages of care for mental, neurological, and substance use disorders in low- and middle-income countries: PLoS Medicine Series. PLoS Med 6 e1000160 doi:10.1371/journal.pmed.1000160
14. ArayaRRojasGFritschRGaeteJRojasM 2003 Treating depression in primary care in low-income women in Santiago, Chile: a randomised controlled trial. Lancet 361 995 1000
15. PatelVChisholmDRabe-HeskethSDias-SaxenaFAndrewG 2003 Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: a randomised, controlled trial. Lancet 361 33 39
16. LiuPHeFFBaiWPYuQShiW 2004 Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine. Chin Med J (Engl) 117 189 194
17. AliBSRahbarMHNaeemSGulAMubeenS 2003 The effectiveness of counseling on anxiety and depression by minimally trained counselors: a randomized controlled trial. Am J Psychother 57 324 336
18. BassJNeugebauerRCloughertyKFVerdeliHWickramaratneP 2006 Group interpersonal psychotherapy for depression in rural Uganda: 6-month outcomes: randomised controlled trial. Br J Psychiatry 188 567 573
19. BoltonPBassJNeugebauerRVerdeliHCloughertyKF 2003 Group interpersonal psychotherapy for depression in rural Uganda: a randomized controlled trial. JAMA 289 3117 3124
20. PatelVWeissHAChowdharyNNaikSPednekarS 2010 Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial. Lancet 376 2086 2095
21. AliNSAliBSAzamISKhuwajaAK 2010 Effectiveness of counseling for anxiety and depression in mothers of children ages 0–30 months by community workers in Karachi, Pakistan: a quasi experimental study. BMC Psychiatry 10 57
22. LiebermanJAPhillipsMGuHStroupSZhangP 2003 Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28 995 1003
23. LiZArthurD 2005 Family education for people with schizophrenia in Beijing, China: randomised controlled trial. Br J Psychiatry 187 339 345
24. RanMSXiangMZChanCLLeffJSimpsonP 2003 Effectiveness of psychoeducational intervention for rural Chinese families experiencing schizophrenia–a randomised controlled trial. Soc Psychiatry Psychiatr Epidemiol 38 69 75
25. ChienWTChanSWThompsonDR 2006 Effects of a mutual support group for families of Chinese people with schizophrenia: 18-month follow-up. Br J Psychiatry 189 41 49
26. BaltieriDADe AndradeAG 2004 Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol 65 136 139
27. BaltieriDAde AndradeAG 2003 Efficacy of acamprosate in the treatment of alcohol-dependent outpatients. Rev Bras Psiquiatr 25 156 159
28. AhmadiJBabaeebeigiMMaanyIPorterJMohagheghzadehM 2004 Naltrexone for alcohol-dependent patients. Ir J Med Sci 173 34 37
29. BaborTFGrantMAcudaWBurnsFHCampilloC 1994 A randomized clinical trial of brief interventions in primary care: summary of a WHO project. Addiction 89 657 660; discussion 660–678
30. DaveUPChauvanVDalviJ 1993 Evaluation of BR-16 A (Mentat) in cognitive and behavioural dysfunction of mentally retarded children–a placebo-controlled study. Indian J Pediatr 60 423 428
31. SzobotCMKetzerCCunhaRDParenteMALanglebenDD 2003 The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder. Eur J Nucl Med Mol Imaging 30 423 426
32. RussellPSal JohnJKLakshmananJL 1999 Family intervention for intellectually disabled children. Randomised controlled trial. Br J Psychiatry 174 254 258
33. LagerkvistB 1992 Community-based rehabilitation–outcome for the disabled in the Philippines and Zimbabwe. Disabil Rehabil 14 44 50
34. Lundgren-LindquistBNordholmLA 1996 The impact of community-based rehabilitation as perceived by disabled people in a village in Botswana. Disabil Rehabil 18 329 334
35. O'TooleB 1988 A community-based rehabilitation programme for pre-school disabled children in Guyana. Int J Rehabil Res 11 323 334
36. PatelVArayaRChatterjeeSChisholmDCohenA 2007 Treatment and prevention of mental disorders in low-income and middle-income countries. Lancet 370 991 1005
37. KnappMFunkMCurranCPrinceMGriggM 2006 Economic barriers to better mental health practice and policy. Health Policy Plan 21 157 170
38. NarasimhanVBrownHPablos-MendezAAdamsODussaultG 2004 Responding to the global human resources crisis. Lancet 363 1469 1472
39. ThirthalliJChandPK 2009 The implications of medication development in the treatment of substance use disorders in developing countries. Curr Opin Psychiatry 22 274 280
40. OdejideAO 2006 Status of drug use/abuse in Africa. Int J Ment Health Addict 4 87 105
41. DieyeAMSyllaMNdiayeANdiayeMSyGY 2006 Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists. Fundam Clin Pharmacol 20 235 238
42. NaqviHA 2005 Mental health care and mental health legislation in Pakistan: no mercy for losers. PLoS Med 2 e397 doi:10.1371/journal.pmed.0020397
43. JainSJadhavS 2009 Pills that swallow policy: clinical ethnography of a Community Mental Health Program in northern India. Transcult Psychiatry 46 60 85
44. PatelVAndradeC 2003 Pharmacological treatment of severe psychiatric disorders in the developing world: lessons from India. CNS Drugs 17 1071 1080
45. PatelV 1995 Explanatory models of mental illness in sub-Saharan Africa. Soc Sci Med 40 1291 1298
46. GhaneSKolkAMEmmelkampPM 2010 Assessment of explanatory models of mental illness: effects of patient and interviewer characteristics. Soc Psychiatry Psychiatr Epidemiol 45 175 182
47. WHO 2009 Improving mental health systems and services for mental health Geneva World Health Organization
48. WHO 2005 WHO-AIMS version 2.2: World Health Organization assessment instrument for mental health systems Geneva World Health Organization
49. WHO 2007 Everybody's business: strengthening health systems to improve health outcomes Geneva World Health Organization
50. WHO 2004 Mental health policy, plans and programmes Geneva World Health Organization
51. TownsendCWhitefordHBainganaFGulbinatWJenkinsR 2004 The mental health policy template: domains and elements for mental health policy formulation. Int Rev Psychiatry 16 18 23
52. WHO 2011 WHO-AIMS - General Information Geneva WHO
53. LoraAKohnRLevavIMcBainRMorrisJ Accessibility, patterns of care and the treatment gap in schizophrenic disorders: A WHO-AIMS survey in 50 low- and middle-income countries. Bull World Health Organ. Available: http://www.who.int/bulletin/online_first/11-089284.pdf. Accessed 26 December 2011. In press
54. World Bank 2010 Country and lending groups Washington (D.C.) The World Bank
55. WHO 2008 Measuring medicine price, availability, affordability and price components Geneva WHO
56. CameronAEwenMRoss-DegnanDBallDLaingR 2009 Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373 240 249
57. NiensLMBrouwerWB 2009 Better measures of affordability required. Lancet 373 1081; author reply 1081–1082
58. UNDP 2010 Human Development Report 2010 – the real wealth of nations: pathways to human development New York United Nations Development Programme
59. O'BrienR 2007 A caution regarding rules of thumb for variance inflation factors. Qual Quant 41 673 690
60. RubinDB 1987 Multiple imputation for nonresponse in surveys New York Wiley
61. CupplesLAHeerenTSchatzkinAColtonT 1984 Multiple testing of hypotheses in comparing two groups. Ann Intern Med 100 122 129
62. WHO 2010 Mental health and development: targeting people with mental health conditions as a vulnerable group Geneva World Health Organization
63. WHO 2008 The global burden of disease–2004 update Geneva World Health Organization
64. SaracenoBvan OmmerenMBatnijiRCohenAGurejeO 2007 Barriers to improvement of mental health services in low-income and middle-income countries. Lancet 370 1164 1174
65. PetersenILundCSteinDJ 2011 Optimizing mental health services in low-income and middle-income countries. Curr Opin Psychiatry 24 318 323
66. FunkMMinolettiADrewNTaylorJSaracenoB 2006 Advocacy for mental health: roles for consumer and family organizations and governments. Health Promot Int 21 70 75
67. KaramustafaliogluO 2010 Major depressive disorder, mental health care, and the use of guidelines in the Middle East. J Clin Psychiatry 71 Suppl E1 e07
68. HickieI 2004 Treatment guidelines for depression in the Asia Pacific region: a review of current developments. Australas Psychiatry 12 Suppl S33 37
69. WHO 2009 WHO model list of essential medicines: 16th list, March, 2009 Geneva World Health Organization
70. LargeMFarooqSNielssenOSladeT 2008 Relationship between gross domestic product and duration of untreated psychosis in low- and middle-income countries. Br J Psychiatry 193 272 278
71. LargeMNielssenOFarooqSGlozierN 2010 Increasing rates of psychiatric publication from low- and middle-income countries. Int J Soc Psychiatry 56 497 506
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2012 Číslo 1
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- Ensemble Modeling of the Likely Public Health Impact of a Pre-Erythrocytic Malaria Vaccine
- Adult Mortality Attributable to Preventable Risk Factors for Non-Communicable Diseases and Injuries in Japan: A Comparative Risk Assessment
- What Will It Take to Eliminate Pediatric HIV? Reaching WHO Target Rates of Mother-to-Child HIV Transmission in Zimbabwe: A Model-Based Analysis
- Challenging Medical Ghostwriting in US Courts